论文部分内容阅读
将2008年3月~2013年5月于我院治疗的120例结核性包裹性胸腔积液患者平分为对照组和试验组,所有患者均行常规抗结核治疗。对照组患者每次抽完积液后,将5mg地塞米松注入积液腔内;试验组患者每次抽完积液后,将10万u尿激酶注射液和20~40ml 0.9%的生理盐水稀释后注入包裹性积液腔。结果对照组痊愈37例,有效10例,有效率78.33%;试验组痊愈49例,有效8例,有效率95.00%,两组差异显著(P<0.05);胸膜平均厚度来看,对照组胸膜平均厚度3.47±0.32mm,试验组胸膜厚度2.51±0.21mm,两组差异显著(P<0.05)。在常规抗结核治疗前提下,将尿激酶注入胸腔,可更快消除积液,同时减轻胸膜的粘连和增厚,是辅助治疗结核性包裹性胸腔积液的有效疗法。
120 patients with tuberculous pleural effusion treated in our hospital from March 2008 to May 2013 were equally divided into control group and experimental group, all patients were treated with conventional anti-TB therapy. Patients in the control group after each pumping fluid, will be 5mg dexamethasone into the effusion chamber; test group of patients after each pumping effusion, the 100,000 urokinase injection and 20 ~ 40ml 0.9% saline Diluted injection of encapsulated fluid chamber. Results The control group was cured in 37 cases, effective in 10 cases, the effective rate was 78.33%; 49 cases were cured in the experimental group, effective in 8 cases, the effective rate was 95.00%, significant difference between the two groups (P <0.05) The mean thickness was 3.47 ± 0.32mm, and the thickness of the pleura in the test group was 2.51 ± 0.21mm. There was significant difference between the two groups (P <0.05). Under the premise of conventional antituberculous therapy, injecting urokinase into the thoracic cavity can eliminate effusion more quickly and reduce pleural adhesions and thickening. It is an effective therapy to help treat tuberculous pleural effusion.